35
Pharma & HealthcareAvoid
Nippon India Pharma
Nippon India · Direct–Growth · rank #14 of 18 by Smart Score
Trailing returns
1 Year
7.5%
+7.0% vs index
3 Years
20.8%
+8.6% vs index
5 Years
13.3%
+1.4% vs index
Since launch
17.6%
Year-by-year performance
2021
+25.1%-5.5% vs index
2022
-9.1%-12.9% vs index
2023
+40.4%+13.8% vs index
2024
+35.3%+19.6% vs index
2025
-2.5%-10.1% vs index
2026
+10.6%+12.4% vs index
Why this score
Nippon India Pharma scores 35/100 — #14 of 18 Pharma & Healthcare fund (Avoid). It stands out for fund size — beating 97% of peers on fund size. The main drag is its 3y return (better than only 15% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return20.81% · 15th percentile in category
5Y return13.35% · 17th percentile in category
Fund size9044.23 Cr · 97th percentile in category
Alpha2.05 · 15th percentile in category
1Y return7.54% · 21st percentile in category
Sharpe ratio1.08 · 44th percentile in category